StudyResults: In the REVIVE study, all participants were essentially phlebotomy free, HCTs maintained at <45%, and ferritin normalized, when rusfertide was added to their treatment. In the PACIFIC study, participants with an average baseline HCT of 51% had their HCT reduced to and maintained at <45% within ~6 weeks of treatment initiation. When a clinical hold necessitated rusfertide dosing interruption, participants had significant (p<0.01) increases in TPs, HCT, and RBC count, and a decrease in serum ferritin. Reinitiating rusfertide normalized hematologic parameters, eliminated TP, and restored ferritin demonstrating the potential effectiveness of rusfertide. Most adverse events (AEs) were grade 1-2. The most frequent AEs were transient injection site reactions reported in 59% of participants.
I tym samym sam sobie odpowiedziałem na poprzednie pytanie - utrzymanie wyżej ferrytyny ma zmniejszyć HCT? Autor tej strony pisał, że ten protokół opiera się na podobnym mechanizmie jak lek Rusfertide.
Zmieniony przez - F1.08 w dniu 2023-08-26 18:08:28
POWERED BY ...